US20090311258A1 - Medicament for lct poisoning - Google Patents

Medicament for lct poisoning Download PDF

Info

Publication number
US20090311258A1
US20090311258A1 US12/376,036 US37603607A US2009311258A1 US 20090311258 A1 US20090311258 A1 US 20090311258A1 US 37603607 A US37603607 A US 37603607A US 2009311258 A1 US2009311258 A1 US 2009311258A1
Authority
US
United States
Prior art keywords
amino acid
tcdb
protein
acid sequence
trembl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/376,036
Inventor
Christoph Von Eichelstreiber
Jessica Reineke
Stefan Tenzer
Hansjoerg Schild
Maja Rupnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johannes Gutenberg Universitaet Mainz
Original Assignee
Johannes Gutenberg Universitaet Mainz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006036373A external-priority patent/DE102006036373A1/en
Priority claimed from DE102007004938A external-priority patent/DE102007004938A1/en
Application filed by Johannes Gutenberg Universitaet Mainz filed Critical Johannes Gutenberg Universitaet Mainz
Assigned to JOHANNES GUTENBERG-UNIVERSITAET MAINZ reassignment JOHANNES GUTENBERG-UNIVERSITAET MAINZ ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHILD, HANSJOERG, RUPNIK, MAJA, REINEKE, JESSICA, TENZER, STEFAN, VON EICHELSTREIBER, CHRISTOPH
Publication of US20090311258A1 publication Critical patent/US20090311258A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the invention relates to a medicament for the prevention or the relief of poisoning by large clostridial cytotoxins (LCTs), in particular Clostridium difficile Toxins A and B (TcdA und TcdB), Clostridium sordellii lethal Toxin (TcsL) and Clostridium novyi ⁇ -Toxin (Tcn ⁇ ).
  • LCTs large clostridial cytotoxins
  • TcdA und TcdB Clostridium difficile Toxins A and B
  • TcsL Clostridium sordellii lethal Toxin
  • Tcn ⁇ Clostridium novyi ⁇ -Toxin
  • Clostridium difficile is a gram-positive, spore-forming germ, growing strictly anaerobically, which was only identified at the end of the 1970s as an etiological agent of antibiotic-associated diarrhea and pseudomembranous colitis. Since the 1990s, C. difficile has been regarded as the most significant hospital germ in developed countries. As a consequence of the continuously expanding use of broad spectrum antibiotics, the incidence of C. difficile infections is constantly increasing further especially in people treated as in-patients.
  • TcdA The exotoxins toxin A (TcdA) and toxin B (TcdB) produced by C. difficile are responsible for the C. difficile -associated diseases.
  • TcdA is an enterotoxin which through cytotoxic damage to the enterocytes increases the permeability of the intestinal mucosa and hence initiates diarrhea.
  • TcdB is a cytotoxin which disturbs the electrolyte transportation and is responsible for loss of fluid and functional disturbances of the intestine.
  • the toxins TcdA and TcdB belong to the group of so-called large clostridial cytoxins (LCTs) and consist respectively of a peptide chain with three functional domains, namely the C-terminal domain, which is responsible for binding the toxin to the host cell membrane, the hydrophobic middle domain, which is made (co)responsible for the translocation process through the cellular membranes, and the N-terminal domain, which has a glycosyltransferase function and imparts the toxic activity of the molecule.
  • LCTs large clostridial cytoxins
  • the uptake process of the toxins in the host cell is in fact not yet fully explained, however it is considered a fact that the toxins, after binding to a host cell receptor, arrive into the host cell by endocytosis, and that for the development of their toxicity the N-terminal catalytic domain is split off and is conveyed into the cytosol of the host cell.
  • the catalytic domain glycolizes specifically GTPases of the Rho sub-family (Rho, Rac and Cdc42), which in turn are involved in an abundance of signal transduction cascades, and in this way blocks the respective signal transduction processes, which finally leads to the disaggregation of the cytoskeleton and to cell death.
  • TcdA and TcdB are autocatalytic processes, which is initiated by inositol phosphate (IP), and that consequently the toxins of Clostridium difficile , in addition to their catalytic function of glycosyltransferase also have the function of a protease for auto-cleavage or autocatalytic cleavage.
  • IP inositol phosphate
  • protease function was identified as aspartate protease.
  • protein region was identified which comprises the amino acid sequence of amino acid position AS 1653 to AS 1678 of TcdB according to sequence No. P18177 (SwissProt/TrEMBL).
  • the motif DXG (Rao et al. 1998) characteristic for aspartate proteases lies at the amino acid position 1665.
  • the protein region was identified which comprises the amino acid sequence of amino acid position AS 1517 to AS 2142 of the TcdB protein according to sequence No. P18177 (SwissProt/TrEMBL).
  • This amino acid sequence constitutes an inosin-5-monophosphate-dehydrogenase (IMPDH) motif, which is composed of two regions, namely AS 1517-AS 1593 and AS 1918-AS 2142, which are separated by a 325 amino acid long protein section without sequence homology.
  • IMPDH inosin-5-monophosphate-dehydrogenase
  • An object of the present invention is the provision of such a medicament.
  • a solution to the said problem consists in the provision of a medicament of the type mentioned in the introduction, which is distinguished in that it contains as active ingredient at least one effector, namely an inhibitor or an activator of the autocatalytic protease activity of LCTs (large clostridial cytotoxins), in particular of the autocatalytic protease activity of Clostridium difficile toxin A (TcdA) and/or Clostridium difficile toxin B (TcdB) and/or Clostridium sordellii lethal toxin (TcsL) and/or Clostridium novyi ⁇ -toxin (Tcn ⁇ ).
  • LCTs large clostridial cytotoxins
  • the active ingredient or effector is an inhibitor
  • its antitoxic effect is based on the fact that it inhibits the protease activity of the intact toxin, in particular of the TcdB or TcdA or TcsL or Tcn ⁇ , and thereby prevents the splitting off of the cytotoxically effective fragment with glucosyltransferase function (in the case of TcdB and TcdA that is the 63 kDa fragment).
  • Suitable inhibitors are chemical substances which inhibit the protease activity of the toxins.
  • Preferred inhibitors are those chemical substances which inhibit the protease activity irreversibly.
  • An example of this is the substance EPNP (1,2-epoxy-3-(p-nitrophenoxy)-propane). The substance reacts irreversibly with aspartate residues in the catalytic centre of proteases and thus inhibits the proteolytic effect.
  • protease inhibitors are known to the specialist in the art or can be easily identified by him by known methods (computer modelling, high throughput screening).
  • a peptide can be synthesized, the amino acid sequence of which corresponds to the sequence of the protease cleavage site of the LCTs.
  • AMC 7-amino-4-methyl-cumarin
  • a probe can be generated.
  • the labelled probe is then brought together with the toxin and the candidate substances. If the probe is split, then changes occur in the fluorescence spectrum. These changes are easy to detect by methods with which the specialist in the art is familiar (fluorescence detectors). Batches in which no change to the fluorescence spectrum are to be observed then contain potential protease inhibitors.
  • the holotoxin or also suitable toxin fragments can be used, which for example are coupled with a dye, the fluorescence of which is quenched in the non-split toxin or toxin fragment.
  • a dye the fluorescence of which is quenched in the non-split toxin or toxin fragment.
  • inhibitors i.e. effectors with inhibitor function are chemical substances, in particular proteins and, amongst these especially antibodies, which inhibit the autocatalytic protease activity of the LCTs by interacting with the active centre of the protease.
  • interact in the present context means any kind of reciprocal action between the LCTs and a chemical substance, in particular a protein, and comprises in particular covalent bonds such as for example disulphide bonds and non-covalent bonds, such as for example van der Waals forces, hydrophobic or electrostatic reciprocal actions and hydrogen bridge bonds.
  • Proteins are preferred here, and amongst these especially antibodies which interact with the TcdB protein region of AS 1500 to AS 1800, in particular from AS 1653 to AS 1678 and especially with the DXG motif at position 1665—respectively according to TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL) or the protein regions equivalent or homologous thereto of TcfA or TcsL or Tcn ⁇ .
  • TcdA the amino acid sequence section of AS 1651 to AS 1675 according to TcdA amino acid sequence No.
  • inhibitors effectors with inhibitor functions
  • suitable inhibitors are chemical substances, in particular proteins and, amongst these especially antibodies, which inhibit the autocatalytic protease activity of the LCTs, by inhibiting the interaction of the inositol phosphate with the toxin. By the IP bond being prevented, the proteolytic cleavage of the toxins does not occur.
  • Proteins are preferred here, and amongst these especially antibodies which interact with the TcdB protein regions of AS 1400 to AS 2300, in particular of AS 1517 to AS 2142 and especially of AS 1517 to AS 1593 or AS 1918 to AS 2142—respectively according to TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL)—or with the protein regions, equivalent or homologous hereto, of the toxins TcdA or TcsL or Tcn ⁇ .
  • antibodies or other proteins can also be generated, which do not interact directly with the inositol phosphate binding site, in particular with the above-mentioned protein regions, but rather are directed towards adjacent regions and hinder the IP binding sterically and hence prevent the proteolytic cleavage of the toxins.
  • antibodies or other proteins can be generated, which do not interact directly with the DXG motif of the protease function of the LCTs, but rather prevent the proteolytic cleavage by binding in adjacent protein sections.
  • Suitable inhibitors are constituted in addition by structural analogues of inositol phosphate (IP) and in particular of inositol hexaphosphate (IP6), which instead of IP and in particular of IP6 can occupy the reaction binding sites of LCT, in particular TcdA and/or TcdB, and/or TcsL and/or Tcn ⁇ , but do not have the initiator function of IP or IP6.
  • These structural analogues are therefore antagonists to the agonists IP (in particular IP6) and bring about a competitive inhibition of the protease activity of LCT, in particular of TcdA and/or TcdB and/or TcsL and/or Tcn ⁇ .
  • Suitable structural analogues are known to the specialist in the art or can be easily identified by known test methods with which the specialist in the art is familiar (examples of these have already been described above).
  • Suitable inhibitors are, in addition, inhibiting substances for/of inositol phosphate (synonyms: inositol phosphate inhibiting substance or inositol phosphate inhibitor), i.e. those inhibiting substances which bind or modify inositol phosphate and in particular inositol hexaphosphate such that its capability of initiating the protease activity of LCT, in particular of TcdA and/or TcdB and/or TcsL and/or Tcn ⁇ is prevented.
  • An example of such substances are bivalent ions such as Ca 2+ , which enter into insoluble complexes with IP6. Similar substances are known to the specialist in the art or can be easily identified by test methods which are known and with which the specialist in the art is familiar (examples of these are already described above).
  • inhibitors effectors with inhibitor function
  • chemical substances which suppress the formation of inositol phosphates in the gut lumen of the patients (mammals, especially humans) or in the body cells of the patients (mammals, especially humans) or destroy already present inositol phosphate and thus prevent the proteolytic cleavage of the LCTs on penetration into the cytoplasm.
  • Preferred examples of such substances are lithium, VPA (valproic acid) or CBZ (carbamazepine).
  • Suitable activators i.e. effectors with activator function, are chemical substances which activate the protease activity of the toxins.
  • the antitoxic effect of an activator is based on the fact that it initiates the protease activity of the intact toxin, in particular of the TcdB or TcdA or TcsL or Tcn ⁇ , still before the toxin has bonded to the host cell such that the split off fragment could arrive into the cell interior (cytosol).
  • the activator consequently brings about a splitting off of the cytotoxically effective fragment with glucosyl transferase function (in the case of TcdB and TcdA, that is the 63 kDa fragment) outside the host cell.
  • the cytotoxically effective fragment can then no longer arrive into the cell interior and develop its cytotoxic effect there.
  • a particularly suitable activator is isolated (in contrast to cytosolic) inositol phosphate (IP), preferably inositol hexaphosphate (IP6).
  • IP inositol phosphate
  • IP6 inositol hexaphosphate
  • a medicament with this active ingredient has the advantage that LCT present in the patient's gut, in particular TcdB and/or TcdA and/or TcsL and/or Tcn ⁇ is already caused to cleave in the gut through the IP supplied as medicament, i.e. before it can bind to gut cells or other body cells and act toxically.
  • Equally suited as activator is a substance which, in an analogous manner to IP6, promotes the autocatalytic protease activity of LCT, in particular of TcdA and/or TcdB and/or TcsL and/or Tcn ⁇ .
  • the catalytic centres of the protease function of the LCTs can also be used according to the invention as systematically administered antigens (vaccination substances) to produce an immunisation against the toxins.
  • the antigen active ingredient(s) is/are preferably selected from the following group of protein fragments:
  • FIG. 1 Cleavage of the TcdB 10463 (270 kDa) holotoxin into the translocation/ligand domain (207 kDa) and the N-terminal catalytic domain (63 kDa) in SDS-PAGE, carried out with
  • FIG. 2 SDS-PAGE of a mixture of TcdB 10463 and/or IP6, with or without pre-treatment of the toxin with EPNP;
  • FIG. 3 ESI-LCMSMS analysis after tryptic digestion of the native (a) and of the EPNP-modified (b) TcdB protein. MS survey scanes (large image) and fragmentation spectra (insert).
  • This pig spleen cell extract was produced as follows: Freshly obtained pig spleen was held in phosphate buffer (PBS) and comminuted to a single cell suspension. Through the addition of low salt buffer,—namely 150 mM NH 4 Cl, 1 mM KHCO 3 , 0.1 mM EDTA, pH 7.6—, erythrocytes which were present were lysed and thereby removed. Then the spleen cells were washed twice with 10 mM Tris-HCl pH 8.5 and deep-frozen immediately at ⁇ 80° C.
  • PBS phosphate buffer
  • the spleen cell extract described in (A) was treated with heat (96° C., 30 minutes), before it was incubated as described in (A) with Cy3-marked TcdB 10463 and was subjected to the SDS-PAGE.
  • the result of this SDS-PAGE is likewise illustrated in FIG. 1 b . Again, the two characteristic 63 kDa and 207 kDa fragments of TcdB 10463 were obtained.
  • IP 6 Inositol hexaphosphate brings about the strongest cleavage activity amongst the tested inositol phosphates, and this means IP 6 has the highest initiator activity (see also FIG. 1 c - e ).
  • Structural analogues or other substances related to the inositol phosphates, which have an initiator activity are known to the specialist in the art or can be easily determined by known methods (e.g. computer modelling). For example, the “High Throughput Assays” described above can also be used.
  • FIGS. 1 c and 1 d The testing out of different concentrations of IP 6 in the incubation experiment with TcdB 10463 shows (see FIGS. 1 c and 1 d ) that for the cleavage of fluorescence-marked toxin B, an IP concentration of 10 ⁇ M ( FIG. 1 c ) is sufficient, whereas for the cleavage of unmarked toxin B (and only made visible in the SDS-PAGE by zinc stain (Zinc Stain and Destain Kit, Biorad, Hercules, USA)), still lower concentrations of up to 1 ⁇ m ( FIG. 1 d ) are sufficient.
  • TcdB specific monoclonal antibody 2CV ProteinG-purified supernate of a serum-free hybridoma culture
  • 2CV ProteinG-purified supernate of a serum-free hybridoma culture
  • HiTrap NHS sepharose column commercially available at GE Healthcare, Freiburg, Federal Republic of Germany
  • Coupling and elution were carried out according to the instructions of the manufacturer.
  • the finished column was charged with approximately 4 mg TcbB 10463 and non-bonded proteins were removed by washing three times with 50 mM tris/HCl, pH 7.0; 125 mM NaCl.
  • the elution took place in one step with 0.1 M triethanolamine-HCl pH11.
  • the toxin eluted in three 4 ml fractions with concentrations between 450-185 ⁇ g/ml.
  • the eluted toxin was immediately neutralized with 1M tris-HCl pH 7.5 in the volume ratio 1/10, which was guaranteed in that these neutralizing solution had already been provided before the start of the elution in the collecting tubes for the fractions.
  • the absence of contaminating proteins was then demonstrated by SDS-PAGE and subsequent zinc stain (see FIG. 1 e “ ⁇ ”).
  • the control experiment consisted of the incubation of unmarked TcdB 10463 , purified in such a way, with IP 6 , and subsequent SDS-PAGE and demonstration of the toxin or of the toxin fragments by means of zinc stain.
  • the result of this experiment is illustrated in FIG. 1 e and shows the complete cleavage of the holotoxin into the two known fragments 63 kDa and 207 kDa.
  • TcdB 10463 was purified as described in Example 1 (D) by means of affinity chromatography with the use of the monoclonal antibody 2CV and then pre-treated either (i) with the protease inhibitor EPNP (10 mM 1,2-epoxy-3-(p-nitrophenoxy)-propane) or (ii)—as control—with buffer (50 mM HEPES, 1M NaCl, 1 mM EDTA, pH 8.0) for 60 minutes at room temperature.
  • EPNP protease inhibitor
  • buffer 50 mM HEPES, 1M NaCl, 1 mM EDTA, pH 8.0
  • Example 1 (A) An in vitro cleavage assay analogous to Example 1 (A) was carried out.
  • the test batches comprised respectively a volume of 10 ⁇ l, and contained respectively 50-100 ng unmarked TcdB 10463 , 100 ⁇ M IP6 and 10 mM tris-HCl pH 8.5. Following the incubation (1 h at room temperature), these test batches were subjected to a SDS-PAGE (10%) and the toxins and toxin fragments were then made visible by means of zinc stain.
  • FIG. 2 shows the result of this experiment:
  • the incubation of TcdB 10463 alone with IP6 (Line 3) shows a distinctly marked band in the molecular weight range of 63 kDa.
  • the toxin is previously pre-treated with EPNP (Line 2), the typical 63 kD band is only weakly marked. This finding shows that through the addition of EPNP, the proteolytic activity (protease activity) of the TcdB 10463 is almost completely inhibited.
  • the toxin pre-treated with EPNP was additionally investigated in the CHO test according to Moos et al. (2000) for its residual activity (cytotoxic effect).
  • the results of this CHO test show that the TcdB 10463 pre-treated with EPNP has a substantially weaker cytotoxic effect than the untreated TcdB 10463 (cf. Table 2).
  • the inhibiting effect of EPNP is based on the fact that EPNP enters into covalent interactions with catalytic aspartate residues and thereby brings about an irreversible inactivation of the protease (Salto et al. 1994)
  • the results of the present experiment show that the inhibiting of the TcdB 10463 activity is based on the inhibiting of a protease activity of this toxin molecule.
  • EPNP constitutes a model substance for a covalent inhibitor of the LCTs.
  • covalently-acting or competitively-inhibiting inhibitors are known to the specialist in the art or can be determined by him by known methods, for example by the already described “high throughput assays”.
  • TcdB 10463 was incubated as described in Example 1 (C) with 100 ⁇ M IP6. Following the incubation, the smaller 63 kD fragment of toxin protein, split off by the protease activity, was separated off, by the batch being purified via microcon tubes (Millipore, exclusion size 100 kD). This 63 kDa fragment of TcdB 10463 was then examined for rounding of the cells in the CHO test according to Moos et al. (2000) described in Example 2. Here, the protein was added undiluted and in dilution stages to the cells.
  • the cytotoxic effect of TcdB 10463 and other LCTs can consequently be inhibited in that the proteolytic cleavage of the toxins is already induced before penetration of the toxins into the cells.
  • EPNP-inactivated (cf. Example 2) and untreated TcdB10463 were separated by means of SDS gel and represented by zinc stain. Then the bands corresponding to the proteins were cut out and divided into small pieces. These were removed of colour and dried, then reduced in 2 mM DTT and alkylated with 20 mM iodacetamide. After the washing and renewed drying of the gel fragments, these were digested with trypsin overnight at 37° C. The resulting peptides were then separated by HPLC (NanoAcquity ultraperformance liquid chromatography, Waters, Milford, USA).
  • the eluted fragments were then examined by mass spectrometry.
  • a Q-T of Premier mass spectrometer of the company Waters was used.
  • the apparatus was calibrated with a [Glu-1]-fibrinogen peptide solution (500 fmol/ ⁇ l at 300 nl/min) via the reference-sprayer of the NanoLockSpray source (Waters).
  • the MassLnyx4.1 software was used.
  • This fragment comprises the amino acids AS 1653 to 1678 of the TcdB protein according to TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL) with the DXG motif at Position 1665, characteristic for aspartate proteases.
  • the specialist in the art can therefore generate antibodies or other proteins by known methods, which interact specifically with the active centre of the protease domain of the toxins, and therefore for example can prevent the autocatalytic cleavage of the LCTs.
  • antibodies or proteins can be generated, which do not directly block the active centre, but rather are directed to adjacent regions and hence prevent the autoproteolytic cleavage of the toxin sterically.
  • TcdB TcdB
  • TcdB fragments were expressed by methods known to the specialist in the art in the plasmid pET-19 (Novagen) and purified via the attached His tag. Then the His tag was split off by means of enterokinase digestion. The purity of the protein was checked in the SDS gel (data not shown).
  • rabbits were firstly initially immunised with the antigen and subsequently subjected to several booster immunisations. Finally, polyclonal antiserums were obtained from the blood of the rabbits.
  • TcdB was pre-treated with polyclonal antiserum (dilution stage 1:100) and incubated for 1 h at room temperature. Then the neutralising effect of the antiserums was checked as described in Example 2 with the aid of the CHO test. The measurement for the neutalising effect of the serums was how long the cells were protected from the cytotoxic effect of the TcdB.
  • the rabbits immunised with preparation A showed only a small antibody titer (cf. Tab. 4), in addition the serum of these rabbits did not have a neutralising effect. This finding corresponds to the results known to the specialist in the art of immunisation experiments with formalised LCTs.
  • the rabbits which had been immunised with the preparations C to E likewise showed an antibody titer, and in addition their polyclonal serums showed a distinctly neutralising effect in the CHO test (Tab. 4).
  • the polyclonal serum which was generated by immunisation with preparation E showed the best neutralising characteristics here.
  • the serums which were produced by separate immunisation with the preparations C and D showed a smaller neutralising effect, compared with this.
  • the neutralising effect of the region around the DSG motif proves that antibodies which are directed against the active centre of the protease can inhibit the proteolytic activity. With such antibodies, therefore, a protection from the toxic effects of the LCTs can also be achieved in vivo.
  • the autocatalytic cleavage of the toxins is important for the natural uptake of the LTCs into their target cells, because only thus is the N-terminal fragment released, imparting the actual toxic activity, in the target cells.
  • the binding of specific antibodies in the environment of the DSG motif of the aspartate protease and the inositol phosphate binding site prevents the autocatalytic cleavage of the toxins. In patients, therefore, through the use of toxin fragments, which are necessary for the autocatalytic cleavage of the LCTs, an effective immunisation against LCTs can be achieved.

Abstract

The medicament for the prevention or the relief of poisoning by large clostridial cytotoxins (LCTs), in particular Clostridium difficile toxins A and B (TcdA and TcdB), is characterized by containing as active ingredient at least one effector, namely an inhibitor or activator of the autocatalytic protease activity of LCTs (large clostridial cytotoxins).

Description

  • The invention relates to a medicament for the prevention or the relief of poisoning by large clostridial cytotoxins (LCTs), in particular Clostridium difficile Toxins A and B (TcdA und TcdB), Clostridium sordellii lethal Toxin (TcsL) and Clostridium novyi α-Toxin (Tcnα).
  • Clostridium difficile is a gram-positive, spore-forming germ, growing strictly anaerobically, which was only identified at the end of the 1970s as an etiological agent of antibiotic-associated diarrhea and pseudomembranous colitis. Since the 1990s, C. difficile has been regarded as the most significant hospital germ in developed countries. As a consequence of the continuously expanding use of broad spectrum antibiotics, the incidence of C. difficile infections is constantly increasing further especially in people treated as in-patients.
  • The exotoxins toxin A (TcdA) and toxin B (TcdB) produced by C. difficile are responsible for the C. difficile-associated diseases. Various strains exist with different virulence and toxin production. Approximately one quarter of all strains produces no toxins. Toxin-forming strains produce almost always both toxins. TcdA is an enterotoxin which through cytotoxic damage to the enterocytes increases the permeability of the intestinal mucosa and hence initiates diarrhea. TcdB is a cytotoxin which disturbs the electrolyte transportation and is responsible for loss of fluid and functional disturbances of the intestine. The toxins TcdA and TcdB belong to the group of so-called large clostridial cytoxins (LCTs) and consist respectively of a peptide chain with three functional domains, namely the C-terminal domain, which is responsible for binding the toxin to the host cell membrane, the hydrophobic middle domain, which is made (co)responsible for the translocation process through the cellular membranes, and the N-terminal domain, which has a glycosyltransferase function and imparts the toxic activity of the molecule.
  • The uptake process of the toxins in the host cell is in fact not yet fully explained, however it is considered a fact that the toxins, after binding to a host cell receptor, arrive into the host cell by endocytosis, and that for the development of their toxicity the N-terminal catalytic domain is split off and is conveyed into the cytosol of the host cell. There, the catalytic domain glycolizes specifically GTPases of the Rho sub-family (Rho, Rac and Cdc42), which in turn are involved in an abundance of signal transduction cascades, and in this way blocks the respective signal transduction processes, which finally leads to the disaggregation of the cytoskeleton and to cell death.
  • In the prior art, hitherto it was assumed that the splitting off of the catalytic N-terminal domain of the toxin peptide chains of TcdA and TcdB and also other “large clostridial toxins” LCT being catalyzed by a cellular protease (Rupnik et al., 2005 and Pfeiffer et al., 2003). Corresponding evidence was not, however, able to be provided.
  • In the course of the investigations which form the basis of the present invention, it was now surprisingly found, however, that the cleavage of TcdA and TcdB is an autocatalytic process, which is initiated by inositol phosphate (IP), and that consequently the toxins of Clostridium difficile, in addition to their catalytic function of glycosyltransferase also have the function of a protease for auto-cleavage or autocatalytic cleavage.
  • This protease function was identified as aspartate protease. As catalytic centre of the protease function, the protein region was identified which comprises the amino acid sequence of amino acid position AS 1653 to AS 1678 of TcdB according to sequence No. P18177 (SwissProt/TrEMBL). The motif DXG (Rao et al. 1998) characteristic for aspartate proteases lies at the amino acid position 1665.
  • As inositol phosphate binding site, the protein region was identified which comprises the amino acid sequence of amino acid position AS 1517 to AS 2142 of the TcdB protein according to sequence No. P18177 (SwissProt/TrEMBL). This amino acid sequence constitutes an inosin-5-monophosphate-dehydrogenase (IMPDH) motif, which is composed of two regions, namely AS 1517-AS 1593 and AS 1918-AS 2142, which are separated by a 325 amino acid long protein section without sequence homology.
  • For the treatment of patients with C. difficile infections, firstly the initiating antibiotic is discontinued, in so far as this is possible. The further treatment takes place exclusively symptomatically. With a long-lasting or serious etiopathology, and when a discontinuance of the initiating antibiotic is not possible for other reasons, metrondiazol or vancomycin is administered for therapy.
  • The disadvantages of the current antimicrobial therapy are manifold. It is critical here above all that a disease which was initiated as a result of the treatment of a different infection situation with antibiotics can not be effectively healed with an antimicrobial therapy. The background to this is the fact that C. difficile only occurs relatively rarely in the gut of healthy people and can not stand up to the normal intestinal flora. If the normal intestinal flora is destroyed by antiobiotic therapy, C. difficile can establish itself and can effectively colonize the gut. The antibiotic therapy directed against C. difficile leads in turn to the destruction of the intestinal flora and thereby causatively also prevents the development of a healthy intestinal flora. This also explains the large number of remissions which are to be observed after completion of the antimicrobial therapy. An additional disadvantage of the current therapy is the increasing occurrence of multiresistant C. difficile strains in recent times. The threat thereby is that the sole therapy hitherto for diseases induced by C. difficile also will become useless and the number of deaths as a result of C. difficile diseases will increase. In addition to this is the fact that the antibiotics necessary for the treatment of a C. difficile infection are very expensive and normally are only used in justified cases as reserve antibiotics.
  • There is therefore an urgent need for medicaments which are suited for the specific combatting (prevention, elimination, relief) of C. difficile infections, without the risk existing of the development of resistances in the clostridia or also other bacteria, and without damaging the natural bacteria flora of the patient concerned—in particular his intestinal flora.
  • An object of the present invention is the provision of such a medicament.
  • A solution to the said problem consists in the provision of a medicament of the type mentioned in the introduction, which is distinguished in that it contains as active ingredient at least one effector, namely an inhibitor or an activator of the autocatalytic protease activity of LCTs (large clostridial cytotoxins), in particular of the autocatalytic protease activity of Clostridium difficile toxin A (TcdA) and/or Clostridium difficile toxin B (TcdB) and/or Clostridium sordellii lethal toxin (TcsL) and/or Clostridium novyi α-toxin (Tcnα).
  • Both activators and also inhibitors of the autocatalytic protease activity of LCTs are designated below as effectors of the autocatalytic protease activity of LCTs.
  • If the active ingredient or effector is an inhibitor, then its antitoxic effect is based on the fact that it inhibits the protease activity of the intact toxin, in particular of the TcdB or TcdA or TcsL or Tcnα, and thereby prevents the splitting off of the cytotoxically effective fragment with glucosyltransferase function (in the case of TcdB and TcdA that is the 63 kDa fragment).
  • Suitable inhibitors are chemical substances which inhibit the protease activity of the toxins.
  • The term “chemical substance” in the above and following explanations designates both inorganic and also organic compounds, ions and peptides or proteins.
  • Preferred inhibitors are those chemical substances which inhibit the protease activity irreversibly. An example of this is the substance EPNP (1,2-epoxy-3-(p-nitrophenoxy)-propane). The substance reacts irreversibly with aspartate residues in the catalytic centre of proteases and thus inhibits the proteolytic effect.
  • Further protease inhibitors are known to the specialist in the art or can be easily identified by him by known methods (computer modelling, high throughput screening). For example, to carry out a high throughput screening, a peptide can be synthesized, the amino acid sequence of which corresponds to the sequence of the protease cleavage site of the LCTs. By coupling this peptide for example with the dye AMC (7-amino-4-methyl-cumarin) by methods which are known to the specialist in the art, a probe can be generated. To carry out the high throughput screenings, the labelled probe is then brought together with the toxin and the candidate substances. If the probe is split, then changes occur in the fluorescence spectrum. These changes are easy to detect by methods with which the specialist in the art is familiar (fluorescence detectors). Batches in which no change to the fluorescence spectrum are to be observed then contain potential protease inhibitors.
  • By way of example, a further method is described for the identification of substances which influence the activation of the autocatalytic protease activity of the PCTs. For this, the holotoxin or also suitable toxin fragments can be used, which for example are coupled with a dye, the fluorescence of which is quenched in the non-split toxin or toxin fragment. Through the autocatalytic cleavage of the toxin or of the toxin fragments, the quenching effect is removed. The changes in the fluorescence spectrum can be easily detected, as described.
  • Particularly suitable inhibitors, i.e. effectors with inhibitor function are chemical substances, in particular proteins and, amongst these especially antibodies, which inhibit the autocatalytic protease activity of the LCTs by interacting with the active centre of the protease.
  • The term “interact” in the present context means any kind of reciprocal action between the LCTs and a chemical substance, in particular a protein, and comprises in particular covalent bonds such as for example disulphide bonds and non-covalent bonds, such as for example van der Waals forces, hydrophobic or electrostatic reciprocal actions and hydrogen bridge bonds.
  • Proteins are preferred here, and amongst these especially antibodies which interact with the TcdB protein region of AS 1500 to AS 1800, in particular from AS 1653 to AS 1678 and especially with the DXG motif at position 1665—respectively according to TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL) or the protein regions equivalent or homologous thereto of TcfA or TcsL or Tcnα. These equivalent/homologous protein regions are, in the case of TcdA, the amino acid sequence section of AS 1651 to AS 1675 according to TcdA amino acid sequence No. P16154 (SwissProt/TrEMBL) with the DXG motif at amino acid position AS 1662, in the case of TcsL, the amino acid sequence section of AS 1654 to AS 1679 according to TcsL amino acid sequence No. Q46342 (SwissProt/TrEMBL) with the DXG motif at amino acid position AS 1666, and in the case of Tcnα, the amino acid sequence section of AS 1641 to AS 1665 according to Tcnα amino acid sequence No. Q46149 (SwissProt/TrEMBL).
  • Further suitable inhibitors (effectors with inhibitor functions) are chemical substances, in particular proteins and, amongst these especially antibodies, which inhibit the autocatalytic protease activity of the LCTs, by inhibiting the interaction of the inositol phosphate with the toxin. By the IP bond being prevented, the proteolytic cleavage of the toxins does not occur.
  • Proteins are preferred here, and amongst these especially antibodies which interact with the TcdB protein regions of AS 1400 to AS 2300, in particular of AS 1517 to AS 2142 and especially of AS 1517 to AS 1593 or AS 1918 to AS 2142—respectively according to TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL)—or with the protein regions, equivalent or homologous hereto, of the toxins TcdA or TcsL or Tcnα.
  • Equally well, antibodies or other proteins can also be generated, which do not interact directly with the inositol phosphate binding site, in particular with the above-mentioned protein regions, but rather are directed towards adjacent regions and hinder the IP binding sterically and hence prevent the proteolytic cleavage of the toxins. Furthermore, antibodies or other proteins can be generated, which do not interact directly with the DXG motif of the protease function of the LCTs, but rather prevent the proteolytic cleavage by binding in adjacent protein sections.
  • Suitable inhibitors (effectors with inhibitor function) are constituted in addition by structural analogues of inositol phosphate (IP) and in particular of inositol hexaphosphate (IP6), which instead of IP and in particular of IP6 can occupy the reaction binding sites of LCT, in particular TcdA and/or TcdB, and/or TcsL and/or Tcnα, but do not have the initiator function of IP or IP6. These structural analogues are therefore antagonists to the agonists IP (in particular IP6) and bring about a competitive inhibition of the protease activity of LCT, in particular of TcdA and/or TcdB and/or TcsL and/or Tcnα. Suitable structural analogues are known to the specialist in the art or can be easily identified by known test methods with which the specialist in the art is familiar (examples of these have already been described above).
  • Suitable inhibitors are, in addition, inhibiting substances for/of inositol phosphate (synonyms: inositol phosphate inhibiting substance or inositol phosphate inhibitor), i.e. those inhibiting substances which bind or modify inositol phosphate and in particular inositol hexaphosphate such that its capability of initiating the protease activity of LCT, in particular of TcdA and/or TcdB and/or TcsL and/or Tcnα is prevented. An example of such substances are bivalent ions such as Ca2+, which enter into insoluble complexes with IP6. Similar substances are known to the specialist in the art or can be easily identified by test methods which are known and with which the specialist in the art is familiar (examples of these are already described above).
  • Further suitable inhibitors (effectors with inhibitor function) are chemical substances which suppress the formation of inositol phosphates in the gut lumen of the patients (mammals, especially humans) or in the body cells of the patients (mammals, especially humans) or destroy already present inositol phosphate and thus prevent the proteolytic cleavage of the LCTs on penetration into the cytoplasm. Preferred examples of such substances are lithium, VPA (valproic acid) or CBZ (carbamazepine).
  • Suitable activators, i.e. effectors with activator function, are chemical substances which activate the protease activity of the toxins.
  • The antitoxic effect of an activator is based on the fact that it initiates the protease activity of the intact toxin, in particular of the TcdB or TcdA or TcsL or Tcnα, still before the toxin has bonded to the host cell such that the split off fragment could arrive into the cell interior (cytosol). The activator consequently brings about a splitting off of the cytotoxically effective fragment with glucosyl transferase function (in the case of TcdB and TcdA, that is the 63 kDa fragment) outside the host cell. The cytotoxically effective fragment can then no longer arrive into the cell interior and develop its cytotoxic effect there.
  • A particularly suitable activator (effector with activator function) is isolated (in contrast to cytosolic) inositol phosphate (IP), preferably inositol hexaphosphate (IP6).
  • A medicament with this active ingredient has the advantage that LCT present in the patient's gut, in particular TcdB and/or TcdA and/or TcsL and/or Tcnα is already caused to cleave in the gut through the IP supplied as medicament, i.e. before it can bind to gut cells or other body cells and act toxically.
  • Equally suited as activator (effector with activator function) is a substance which, in an analogous manner to IP6, promotes the autocatalytic protease activity of LCT, in particular of TcdA and/or TcdB and/or TcsL and/or Tcnα.
  • Such substances are known to the specialist in the art or can be easily identified by known methods. In addition, modified variants of the “high throughput assays” described above are also suitable for this. Here, the toxin and the potential activator substances are added together and in the course of time, changes in the fluorescence spectrum are sought. Batches in which intensive changes occur in a short period of time contain suitable activators (effectors with activator function).
  • The catalytic centres of the protease function of the LCTs can also be used according to the invention as systematically administered antigens (vaccination substances) to produce an immunisation against the toxins. The subject of the present invention is therefore also a medicament for the prevention or the relief of poisoning by LCT (=large clostridial cytotoxins), which is characterized in that it is suitable for administration as a vaccine, and that it has the amino acid sequence of the catalytic centre of TcdB and/or TcdA and/or TcsL and/or Tcnα, wholly or fragments thereof as antigen active ingredient(s). The antigen active ingredient(s) is/are preferably selected from the following group of protein fragments:
      • DXG motif at position 1665 of the TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL),
      • the amino acid positions AS 1653 to AS 1678 of the TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL),
      • the amino acid positions AS 1500 to AS 1800 of the TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL),
      • the DXG motif at position 1662 of the TcdA amino acid sequence No. P16154 (SwissProt/TrEMBL),
      • the amino acid positions AS 1651 to AS 1675 of the TcdA amino acid sequence No. P16154 (SwissProt/TrEMBL)
      • the DXG motif at position 1666 of the TcsL amino acid sequence No. Q46342 (Swissprot/TrEMBL)
      • the amino acid positions AS 1654 bis AS 1679 of the TcsL amino acid sequence No. Q46342 (SwissProt/TrEMBL),
      • the amino acid positions AS 1641 to AS 1665 of the Tcnα amino acid sequence No. Q46149 (SwissProt/TrEMBL).
  • The invention is described in further detail below with the aid of example embodiments and figures, showing:
  • FIG. 1: Cleavage of the TcdB10463 (270 kDa) holotoxin into the translocation/ligand domain (207 kDa) and the N-terminal catalytic domain (63 kDa) in SDS-PAGE, carried out with
      • a: a mixture of Cy3-marked TcdB10463 and pig spleen cell extract (Example 1 A);
      • b: a mixture of Cy3-marked TcdB10463 and pig spleen cell extract freed of protein (Example 1 B);
      • c: a mixture of Cy3-marked TcdB10463. and inositol phosphate;
      • d: a mixture of unmarked TcdB10463. and inositol phosphate;
      • e: a mixture of unmarked (purified by means of affinity chromatography) TcdB10463 and inositol phosphate;
      • a-e respectively following an incubation at room temperature for 1 hour
  • FIG. 2: SDS-PAGE of a mixture of TcdB10463 and/or IP6, with or without pre-treatment of the toxin with EPNP;
      • Line 1: TcdB10463 after pre-treatment with EPNP and without IP6, no band able to be evidenced in the 63 kDa range;
      • Line 2: TcdB10463 after pre-treatment with EPNP and after incubation with IP6, the typical 63 kD band is only weakly formed;
      • Line 3: TcdB10463 without pre-treatment with EPNP and after incubation with IP6, a distinctly formed band can be seen in the molecular weight range of 63 kDa;
      • Line 4: TcdB10463 without pre-treatment with EPNP and without IP6, no band is able to be evidenced in the 63 kDa range;
  • FIG. 3: ESI-LCMSMS analysis after tryptic digestion of the native (a) and of the EPNP-modified (b) TcdB protein. MS survey scanes (large image) and fragmentation spectra (insert).
    •
  • All the methods named in the following examples are known to the specialist in the art and are described for example in Ausubel et al. (2003).
    • EXAMPLE 1 Evidence of the Autocatalytic Protease Activity of TcdB
  • Clostridium difficile toxin B (270 kDa) of the reference strain VPI10463, abbreviated below to TcdB10463, was initially fluorescence-marked with Cy3.
  • For this, 200-400 μg TcdB10463 (tgcBIOMICS, Mainz, Germany) were marked with the dye Cy3 in accordance with the instructions of the manufacturer (Amersham Biosciences), by the toxin being incubated with the dye, dissolved in dimethyl formamide, for 1 hour at 4° C. Non-bonded dye was then removed by means of size exclusion chromatography (=SEC), in which 10 mM Tris-HCl pH 8.5 served as run buffer. The molar ratio between dye and Cy3-marked TcdB10463 was 0.8-1.6. Marked TcdB10463 was aliquoted and stored at −80° C. until further use.
  • (A) To carry out the “In-vitro-cleavage-assay” known from the prior art (see in this respect in particular Rupnik et al (2005); reference is hereby made expressly to the content of this publication) an aliquot Cy3-marked TcdB10463, thawed to room temperature, was incubated for 1 hour at room temperature with pig spleen cell extract.
  • This pig spleen cell extract was produced as follows: Freshly obtained pig spleen was held in phosphate buffer (PBS) and comminuted to a single cell suspension. Through the addition of low salt buffer,—namely 150 mM NH4Cl, 1 mM KHCO3, 0.1 mM EDTA, pH 7.6—, erythrocytes which were present were lysed and thereby removed. Then the spleen cells were washed twice with 10 mM Tris-HCl pH 8.5 and deep-frozen immediately at −80° C. For the desired cell extract, as required an aliquot of these deep-frozen spleen cells was thawed in an aliquot 10 mM Tris-HCl pH 8.5 and suspended and this suspension was then subjected to an ultrasonic treatment. The obtained lysate was centrifuged for 1 hour at 200 000×g and 4° C. and the supernate was used for the upcoming experiments.
  • At the end of the incubation phase, the mixture of Cy3-marked TcdB10463 and pig spleen extract was subjected to a SDS-PAGE, in order to separate and detect the TcdB fragments which occurred during the incubation. The result of this SDS-PAGE is illustrated in FIG. 1 a: As expected, the two known and characteristic 63 kDa and 207 kDa fragments of the Clostridium difficile Toxin B—here the TcdB10463—were obtained.
  • Aliquots of TcdB10463 without admixture of spleen cell extract served as negative controls (see FIG. 1 “−”).
  • (B) In a parallel experiment, the spleen cell extract described in (A) was purified of protein before the incubation with the Cy3-marked TcdB10463. For this purpose, an aliquot of the pig spleen extract produced according to (A) was subjected to six phenol-chloroform extractions, following the ultrasonic treatment, which extractions were carried out as follows: Pig spleen extract was mixed with phenol-chloroform-isoamyl alcohol (25/24/1) in the volume ratio 1:1. This mixture was centrifuged for 10 minutes at 1,7000×g and 4° C. The aqueous uppermost layer was decanted into a fresh centrifuge vessel and centrifuging and decanting was repeated for a further five times. In order to also remove final residues of phenol, finally a chloroform extraction was carried out.
  • Aliquots of the aqueous and protein-free fraction of the spleen cell extract obtained in this way were diluted in the volume ratio 1:30 (30), 1:100 (100) or 1:300 (300) with 10 mM tris-HCL pH8.5 and, as described under (A), mixed with aliquots of Cy3-marked TcdB10463, thawed to room temperature, and incubated for 1 hour at room temperature. At the end of the incubation phase, these mixtures were subjected to a SDS-PAGE, in order to separate and detect the TcdB fragments which occurred during the incubation. The result of this SDS-PAGE was made visible by means of the Gel Doc EQ system image readers (BIO-RAD Munich, Germany) and is illustrated in FIG. 1 b: In all test batches the two characteristic 63 kDa and 207 kDa fragments of TcdB10463 were obtained. This shows that the aqueous and protein-free fraction of the spleen cell extract still has or had the characteristic of splitting TcdB10463 into its two characteristic partial fragments.
  • In a further parallel experiment, the spleen cell extract described in (A) was treated with heat (96° C., 30 minutes), before it was incubated as described in (A) with Cy3-marked TcdB10463 and was subjected to the SDS-PAGE. The result of this SDS-PAGE is likewise illustrated in FIG. 1 b. Again, the two characteristic 63 kDa and 207 kDa fragments of TcdB10463 were obtained.
  • The result shows that the heat-induced spleen cell extract continues to have the characteristic of splitting TcdB10463 into its characteristic partial fragments.
  • (C) In a further series of experiments, Cy3-marked TcdB10463 and unmarked TcdB10463 were incubated alone (i.e. without the admixture of spleen cell extract) with various inositol phosphates for 1 hour at room temperature and the respective mixtures were then subjected to a SDS-PAGE. The result of these investigations is illustrated in Table 1 and in FIGS. 1 c-e and provide the surprising core conclusions, that the proteolytic cleavage of TcdB10463 is able to be initiated solely through a chemical substance such as IP, and that this proteolytic cleavage is consequently an autocatalytic process of the toxin protein.
  • From Table 1, it can be seen that a range of inositol phosphates can initiate the autocatalytic cleavage of TcdB10463. Inositol hexaphosphate (IP6) brings about the strongest cleavage activity amongst the tested inositol phosphates, and this means IP6 has the highest initiator activity (see also FIG. 1 c-e).
  • Structural analogues or other substances related to the inositol phosphates, which have an initiator activity, are known to the specialist in the art or can be easily determined by known methods (e.g. computer modelling). For example, the “High Throughput Assays” described above can also be used.
  • The testing out of different concentrations of IP6 in the incubation experiment with TcdB10463 shows (see FIGS. 1 c and 1 d) that for the cleavage of fluorescence-marked toxin B, an IP concentration of 10 μM (FIG. 1 c) is sufficient, whereas for the cleavage of unmarked toxin B (and only made visible in the SDS-PAGE by zinc stain (Zinc Stain and Destain Kit, Biorad, Hercules, USA)), still lower concentrations of up to 1 μm (FIG. 1 d) are sufficient.
  • Analogous experiments were also carried out with the LCTs TcdA10463, TcsL of C. sordellii and Tcnα. Here it was found that inositol phosphates have an activating effect on the autocatalytic cleavage of all investigated toxins of the LCT family.
  • (D) In order to rule out that the TcdB10463, purified from culture supernate of C. difficile, used in the experiments, was contaminated with proteases, a control experiment with especially purified TcdB10463 was carried out. This purification of the TcdB10463 took place by means of affinity chromatography with the use of the monoclonal antibody 2CV (DSM ACC 2321) as follows:
  • 7 mg of the TcdB specific monoclonal antibody 2CV (ProteinG-purified supernate of a serum-free hybridoma culture) was coupled to a HiTrap NHS sepharose column (commercially available at GE Healthcare, Freiburg, Federal Republic of Germany). Coupling and elution were carried out according to the instructions of the manufacturer. The finished column was charged with approximately 4 mg TcbB10463 and non-bonded proteins were removed by washing three times with 50 mM tris/HCl, pH 7.0; 125 mM NaCl. The elution took place in one step with 0.1 M triethanolamine-HCl pH11. The toxin eluted in three 4 ml fractions with concentrations between 450-185 μg/ml. The eluted toxin was immediately neutralized with 1M tris-HCl pH 7.5 in the volume ratio 1/10, which was guaranteed in that these neutralizing solution had already been provided before the start of the elution in the collecting tubes for the fractions. The absence of contaminating proteins was then demonstrated by SDS-PAGE and subsequent zinc stain (see FIG. 1 e “−”).
  • The control experiment consisted of the incubation of unmarked TcdB10463, purified in such a way, with IP6, and subsequent SDS-PAGE and demonstration of the toxin or of the toxin fragments by means of zinc stain. The result of this experiment is illustrated in FIG. 1 e and shows the complete cleavage of the holotoxin into the two known fragments 63 kDa and 207 kDa.
    • EXAMPLE 2 Inactivation of TcdB-10463 through Incubation with a Protease Inhibitor
  • TcdB10463 was purified as described in Example 1 (D) by means of affinity chromatography with the use of the monoclonal antibody 2CV and then pre-treated either (i) with the protease inhibitor EPNP (10 mM 1,2-epoxy-3-(p-nitrophenoxy)-propane) or (ii)—as control—with buffer (50 mM HEPES, 1M NaCl, 1 mM EDTA, pH 8.0) for 60 minutes at room temperature.
  • Then an in vitro cleavage assay analogous to Example 1 (A) was carried out. The test batches comprised respectively a volume of 10 μl, and contained respectively 50-100 ng unmarked TcdB10463, 100 μM IP6 and 10 mM tris-HCl pH 8.5. Following the incubation (1 h at room temperature), these test batches were subjected to a SDS-PAGE (10%) and the toxins and toxin fragments were then made visible by means of zinc stain.
  • FIG. 2 shows the result of this experiment: The incubation of TcdB10463 alone with IP6 (Line 3) shows a distinctly marked band in the molecular weight range of 63 kDa. When the toxin is previously pre-treated with EPNP (Line 2), the typical 63 kD band is only weakly marked. This finding shows that through the addition of EPNP, the proteolytic activity (protease activity) of the TcdB10463 is almost completely inhibited.
  • The toxin pre-treated with EPNP was additionally investigated in the CHO test according to Moos et al. (2000) for its residual activity (cytotoxic effect).
  • The CHO test was carried out as follows: In a 96 well microtiter plate, CHO cells (=Chinese hamster ovarial cells) were disseminated (5000 cells/well) and incubated for 16 hours under standard conditions (5% CO2, DMEM F12 supplemented with 2 mN L-glutamins, 5% FCS). The toxins were then introduced to the cells after gradual dilution in growth medium. Dilution stages between 100 and 10−8 were tested. The cells were incubated for 3 hours under standard conditions. Then the proportion of rounded cells was determined microscopically, by several representative sections of the well being photographed and the elongated and the rounded cells being counted. (See also Moos et al., Meth Enzymol. 2000, 325: 114-125. Reference is made here expressly to the content of this publication).
  • The results of this CHO test show that the TcdB10463 pre-treated with EPNP has a substantially weaker cytotoxic effect than the untreated TcdB10463 (cf. Table 2). As the inhibiting effect of EPNP, as is known, is based on the fact that EPNP enters into covalent interactions with catalytic aspartate residues and thereby brings about an irreversible inactivation of the protease (Salto et al. 1994), the results of the present experiment show that the inhibiting of the TcdB10463 activity is based on the inhibiting of a protease activity of this toxin molecule.
  • The experiment with EPNP described here proves that the toxic effect of TcdB-0463 and other LCTs is significantly reduced by pre-treatment of the toxins with a suitable protease inhibitor.
  • EPNP constitutes a model substance for a covalent inhibitor of the LCTs. Further comparably covalently-acting or competitively-inhibiting inhibitors are known to the specialist in the art or can be determined by him by known methods, for example by the already described “high throughput assays”.
    • EXAMPLE 3 Inactivation of the Cytotoxic Effect of TcdB10463 through Extracellular Activation of the Protease Activity with IP6
  • TcdB10463 was incubated as described in Example 1 (C) with 100 μM IP6. Following the incubation, the smaller 63 kD fragment of toxin protein, split off by the protease activity, was separated off, by the batch being purified via microcon tubes (Millipore, exclusion size 100 kD). This 63 kDa fragment of TcdB10463 was then examined for rounding of the cells in the CHO test according to Moos et al. (2000) described in Example 2. Here, the protein was added undiluted and in dilution stages to the cells.
  • In this experiment, it was found that the 63 kDa fragment, which has the glucosyltransferase function of TcdB10463, under the given conditions alone is/was not able to bring about a cytotoxic effect. Neither in diluted nor in undiluted state a rounding of the cells (as a consequence of a glucosilation of specific GTpases of the Rho sub-family, which results in a blocking of signal transduction processes which results in a disaggregation of the cytoskeleton) could be observed. This finding that the toxin fragment generated by means of autocatalysis is inactive extracellularly, confirms the results of Pfeifer et al. (2003) and Rupnik et al (2005), which show that the split-off catalytic domain of TcdB10463 is not taken up into eucaryontic cells and is therefore inactive in the cell medium. (Whereas in these papers, however, an autocatalytic activity of the LCTs is explicitly ruled out [Pfeifer et al., 2003] or there is speculation concerning a cellular protease for the activation of the LCTs [Rupnik et al., 2005], the experiment results obtained in connection with the present invention show for the first time that the N-terminal toxin fragment is split off autocatalytically).
  • The cytotoxic effect of TcdB10463 and other LCTs can consequently be inhibited in that the proteolytic cleavage of the toxins is already induced before penetration of the toxins into the cells.
    • EXAMPLE 4 Demonstration of the Active Centre of the Protease of TcdB
  • EPNP-inactivated (cf. Example 2) and untreated TcdB10463 were separated by means of SDS gel and represented by zinc stain. Then the bands corresponding to the proteins were cut out and divided into small pieces. These were removed of colour and dried, then reduced in 2 mM DTT and alkylated with 20 mM iodacetamide. After the washing and renewed drying of the gel fragments, these were digested with trypsin overnight at 37° C. The resulting peptides were then separated by HPLC (NanoAcquity ultraperformance liquid chromatography, Waters, Milford, USA). For this, 2 μl of the samples were applied onto a reverse-phase column (NanoEase BEH C18 (75 μm×10 cm) of Waters, Milford, USA) in 2% mobile phase B buffer (0.1% formic acid in acetonitrile). Mobile phase A buffer contained 0.1% formic acid in H2O. Then the fragments were eluted through a gradient of 3-40% mobile phase B buffer (90 min at 300 nl/min) from the column.
  • The eluted fragments were then examined by mass spectrometry. For this, a Q-T of Premier mass spectrometer of the company Waters was used. The apparatus was calibrated with a [Glu-1]-fibrinogen peptide solution (500 fmol/μl at 300 nl/min) via the reference-sprayer of the NanoLockSpray source (Waters). For the analysis of the results, the MassLnyx4.1 software (Waters) was used.
  • The analysis of the results shows that the untreated TcdB differs from the EPNP-treated toxin only in a tryptic fragment (Illustration 3). This fragment comprises the amino acids AS 1653 to 1678 of the TcdB protein according to TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL) with the DXG motif at Position 1665, characteristic for aspartate proteases.
  • A comparison of the amino acid sequence AS 1653 to AS 1678 of the catalytic centre of TcdB with the corresponding catalytic centres and protein regions of the toxins TcdA, TcsL and Tcnα shows that the region is highly conserved (see Tab. 3).
  • The specialist in the art can therefore generate antibodies or other proteins by known methods, which interact specifically with the active centre of the protease domain of the toxins, and therefore for example can prevent the autocatalytic cleavage of the LCTs. Equally well, antibodies or proteins can be generated, which do not directly block the active centre, but rather are directed to adjacent regions and hence prevent the autoproteolytic cleavage of the toxin sterically.
    • EXAMPLE 5 Inhibition of the TcdB Effect through Antibodies as a Result of Immunisation with Inactivated TcdB
  • In order to induce a protection against the cytotoxic effects of TcdB, the following TcdB preparations were produced and used for immunisation in rabbits:
      • Preparation A: TcdB, inactivated with formalin
      • Preparation B: TcdB, inactivated with EPNP (cf. Example 2)
      • Preparation C: TcdB fragment AS1601-1716 (DSG motif)
      • Preparation D: TcdB fragment AS1508-1601 (part of the inosine-binding motif)
      • Preparation E: TcdB fragments AS1508-2157
        • (Dsg motif and entire inosine-binding motif)
  • The TcdB fragments were expressed by methods known to the specialist in the art in the plasmid pET-19 (Novagen) and purified via the attached His tag. Then the His tag was split off by means of enterokinase digestion. The purity of the protein was checked in the SDS gel (data not shown).
  • For immunisation, rabbits were firstly initially immunised with the antigen and subsequently subjected to several booster immunisations. Finally, polyclonal antiserums were obtained from the blood of the rabbits.
  • In order to check the neutralising effect of the polyclonal antiserums, firstly TcdB was pre-treated with polyclonal antiserum (dilution stage 1:100) and incubated for 1 h at room temperature. Then the neutralising effect of the antiserums was checked as described in Example 2 with the aid of the CHO test. The measurement for the neutalising effect of the serums was how long the cells were protected from the cytotoxic effect of the TcdB.
  • The rabbits immunised with preparation A showed only a small antibody titer (cf. Tab. 4), in addition the serum of these rabbits did not have a neutralising effect. This finding corresponds to the results known to the specialist in the art of immunisation experiments with formalised LCTs.
  • The animals which were immunised with preparation B did indeed develop a distinct titer (dilutable up to 1:1500), however this antiserum also did not show any neutralising effect in the CHO test (Tab. 4).
  • The rabbits which had been immunised with the preparations C to E likewise showed an antibody titer, and in addition their polyclonal serums showed a distinctly neutralising effect in the CHO test (Tab. 4). The polyclonal serum which was generated by immunisation with preparation E showed the best neutralising characteristics here.
  • The serums which were produced by separate immunisation with the preparations C and D showed a smaller neutralising effect, compared with this.
  • The success of the immunisation with fragment D, which comprises a part of the inositol-binding region, proves that this section of the LCTs is an important region for the activation of the toxins. The binding of the IP6 in this toxin section leads to the activation of the autocatalytic protease activity and hence also to the activation of the LCTs.
  • The neutralising effect of the region around the DSG motif proves that antibodies which are directed against the active centre of the protease can inhibit the proteolytic activity. With such antibodies, therefore, a protection from the toxic effects of the LCTs can also be achieved in vivo.
  • With the immunisation with preparation E, only the two fragments of the successful preparations C and D were used together. The success of the immunisation with both TcdB fragments is based on the fact that in the animals antibodies are induced which are directed towards the active centre of the protease and also those antibodies which bind to the inositol phosphate-binding region. The effect of the antiserum is therefore based on the fact that for the first time specific antibodies were able to be induced, which systematically prevent the activation of the toxin.
  • The autocatalytic cleavage of the toxins is important for the natural uptake of the LTCs into their target cells, because only thus is the N-terminal fragment released, imparting the actual toxic activity, in the target cells. The binding of specific antibodies in the environment of the DSG motif of the aspartate protease and the inositol phosphate binding site prevents the autocatalytic cleavage of the toxins. In patients, therefore, through the use of toxin fragments, which are necessary for the autocatalytic cleavage of the LCTs, an effective immunisation against LCTs can be achieved.
    • LITERATURE
    • Ausubel, F. M. et al.: “Current Protocols in Molecular Biology” (2003), John Wiley and Sons. Inc.
    • Rupnik et al. (2005) “Characterization of the cleavage site and function of resulting cleavage fragments after limited proteolysis of Clostridium difficile toxin B(TcdB) by host cells.” Mikrobiol 151, 199-208.
    • Moos et al. (2000) “Purification and evaluation of large clostridial cytotoxins that inhibit small GTPases of Rho and Ras subfamilies” Meth Enzymol. 325: 114-125.
    • Pfeifer et al. (2003) “Cellular Uptake of Clostridium difficile toxins B” J. Biol. Chem. 278: 44535-41.
    • Rao et al. (1998) “Molecular and biotechnological aspects of microbial proteases” Microbiol. Mol. Biol. Rev. 62: 597-635.
    • Salto et al. (1994) “In vitro characterization of nonpeptide irreversible inhibitors of HIV proteases”, J. Biol. Chem. 269: 10691-8.
    • Tang (1971) “Specific and irreversible inactivation of pepsin by substrate-like Epoxides”, J. Biol. Chem. 246: 4510-17.
  • TABLE 1
    Autocatalytic cleavage of TcdB10463 with the
    addition of defined inositol phosphates
    Concentration
    IP
    1 mM 100 μM 10 μM
    1, 5 − − −
    1, 4 − − −
    4, 5 − − −
    1, 4, 5 − − −
    2, 3, 5 − − −
    1, 3, 5 − − −
    1, 3, 5, 6 − − −
    1, 2, 3, 4, 6 − − −
    1, 3, 4 + − −
    1, 3, 4, 5 + − −
    3, 4, 6 + − −
    1, 2, 3, 4 + − −
    1, 2, 3, 4, 5 + − −
    1, 2, 3, 5, 6 + + −
    1, 3, 4, 5, 6 + + −
    3, 4, 5, 6 + + −
    2, 3, 4, 5, 6 + + −
    1, 4, 5, 6 + + −
    1, 2, 3, 4, 5, 6 + + +
  • TABLE 2
    Cell rounding (in %) of CHO cells after incubation
    with TcdB10463 - with or without EPNP pre-treatment
    Rounded cells [%] after 3 h
    Dilution TcdB-10463 TcdB-10463 + EPNP
    10−3 100% 100%
    10−4 100% 100%
    10−5 100%  50%
    10−6 100%  10%
    10−7  10%  <5%
    10−8  <5%  <5%
  • TABLE 3
    Comparison of the amino acid sequence AS 1653
    to AS 1678 of the catalytic centre of the
    protease function of TcdB with the corresponding
    catalytic centres and protein regions of the
    toxins TcdA, TcsL and Tcnα
    Toxin Homologous Sequence Range
    TcdB-10463 1653-QNMIVEPNYDLDDSGDISSTVINFSQ-1678
    TcdA-10463 1649-RNVVVEPIYNPDTGEDISTSL-DFSY-1675
    TcsL 1654-QNLIVEPSYHLDDSGNISSTVINFSQ-1679
    Tcnα 1638-CNVIVSGSNKLNSEGDLADT-IDVLD-1663
  • TABLE 4
    Start of cell rounding (in h) of CHO cells after incubation
    with TcdB, which was pre-treated with polyclonal antiserum.
    Preparation Antibody Titer Start of cell rounding after
    A 1:100 1.5 h
    B  1:1500 3 h
    C 1:750 12-15 h
    D 1:500 9-12 h
    E  1:1000 >24 h

Claims (20)

1. Medicament for prevention or relief of poisoning by LCT (=large clostridial cytotoxins), comprising, as active ingredient at least one effector, wherein said at least one effector is an inhibitor or activator of a protease activity of said LCT.
2. Medicament according to claim 1, wherein said at least one effector is an inhibitor or activator of a protease activity of Clostridium difficile toxin A (TcdA) and/or Clostridium difficile toxin B (TcdB) and/or Clostridium sordellii lethal toxin (TcsL) and/or Clostridium novyi α-toxin (Tcnα).
3. Medicament according to claim 1, wherein the inhibitor is 1,2-epoxy-3-(p-nitrophenoxy)-propane (EPNP).
4. Medicament according to claim 3, wherein the activator is an inositol phosphate, preferably inositol hexaphosphate (IP6).
5. Medicament according to claim 1, wherein the effector is a competitively inhibiting structural analogue of inositol phosphate, preferably inositol hexaphosphate (IP6).
6. Medicament according to claim 1, wherein the activator is a substance which analogous to IP6 promotes (autocatalytic) protease activity of LCTs, in particular of TcdA and/or TcdB and/or TcsL and/or Tcnα.
7. Medicament according to claim 1, wherein the effector is a chemical substance that reduces inositol phosphate concentration in gut lumen of mammals, in particular humans.
8. Medicament according to claim 1, wherein the effector is a chemical substance that reduces inositol phosphate concentration in mammalian cells, in particular human cells.
9. Medicament according to claim 1, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody, which interacts with an active centre of the protease in TcdB protein region of AS 1500 to AS 1800 according to TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL).
10. Medicament according to claim 1, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody which interacts with TcdB protein region of AS 1653 to AS 1678 according to TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL).
11. Medicament according to claim 1, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody, which interacts with the DXG motif at amino acid position AS 1665 of the TcdB protein according to TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL).
12. Medicament according to claim 1, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody which interacts with TcdA protein region of AS 1651 to AS 1675 according to TcdA amino acid sequence No. P16154 (SwissProt/TrEMBL).
13. Medicament according to claim 1, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody which interacts with a DXG motif at amino acid position AS 1662 of a TcdA protein according to TcdA amino acid sequence No. P16154 (SwissProt/TrEMBL).
14. Medicament according to claim 1, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody which interacts with TcsL protein region of AS 1654 to AS 1679 according to TcsL amino acid sequence No Q46342 (SwissProt/TrEMBL).
15. Medicament according to claim 1, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody which interacts with a DXG motif at amino acid position AS 1666 of a TcsL protein according to TcsL amino acid sequence No. Q46342 (SwissProt/TrEMBL).
16. Medicament according to claim 1, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody which interacts with a Tcnα protein region of AS 1641 to AS 1665 according to Tcnα amino acid sequence No Q46149 (SwissProt/TrEMBL).
17. Medicament according to claim 1, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody which interacts with a TcdB protein region of AS 1400 to AS 2300 according to TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL) or with protein regions of TcdA or TcsL or Tcnα equivalent or homologous thereto.
18. Medicament according to claim 1, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody which interacts with a TcdB protein region of AS 1517 to AS 2142 according to TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL) or with protein regions of TcdA or TcsL or Tcnα equivalent or homologous thereto.
19. Medicament according to claim 1, wherein the inhibitor is a chemical substance, in particular a protein, more particularly an antibody which interacts with a TcdB protein region of AS 1517 to AS 1593 or of AS 1918 to AS 2142 according to TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL) or with protein regions of TcdA or TcsL or Tcnα equivalent or homologous thereto.
20. Medicament for prevention or relief of poisoning by LCT (=large clostridial cytotoxins), wherein the medicament
(1.) is suited for administration as a vaccine and
(2.) as an antigen active ingredient
(a) contains a TcdB protein fragment of TcdB amino acid sequence No. P18177 (SwissProt/TrEMBL) which comprises at least a DXG motif at position 1665, preferably an amino acid sequence of amino acid positions AS 1653 to AS 1678 and more preferably an amino acid sequence of amino acid positions AS 1500 to AS 1800,
and/or (b) contains a TcdA protein fragment of TcdA amino acid sequence No. P16154 (SwissProt/TrEMBL), which comprises at least a DXG motif at position 1662, preferably an amino acid sequence of amino acid positions AS 1651 to AS 1675,
and/or (c) contains a TcsL protein fragment of TcsL amino acid sequence No. Q46342 (SwissProt/TrEMBL), which comprises at least a DXG motif at position 1666, preferably an amino acid sequence of amino acid positions AS 1654 to AS 1679,
and/or (d) contains a Tcnα protein fragment of Tcnα amino acid sequence No. Q46149 (SwissProt/TrEMBL), which comprises at least an amino acid sequence of AS 1641 to AS 1665.
US12/376,036 2006-08-02 2007-05-26 Medicament for lct poisoning Abandoned US20090311258A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102006036373A DE102006036373A1 (en) 2006-08-02 2006-08-02 Medicament, useful e.g. for the avoidance or alleviation of a poisoning by large clostridial cytotoxins and to combat Clostridium difficile infection, comprises inhibitor or activator of protease activity of clostridial cytotoxin
DE102006036373.6 2006-08-02
DE102007004938.4 2007-01-26
DE102007004938A DE102007004938A1 (en) 2007-01-26 2007-01-26 Medicament for avoiding or alleviating large clostridial cytotoxins, comprises an effector, which is an inhibitor or activator of the protease activity of large clostridial cytotoxins
PCT/DE2007/000957 WO2008014733A1 (en) 2006-08-02 2007-05-26 Medicament for lct poisoning

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2007/000957 A-371-Of-International WO2008014733A1 (en) 2006-08-02 2007-05-26 Medicament for lct poisoning

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/483,701 Continuation US9066961B2 (en) 2006-08-02 2012-05-30 Medicament for LCT poisoning

Publications (1)

Publication Number Publication Date
US20090311258A1 true US20090311258A1 (en) 2009-12-17

Family

ID=38521891

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/376,036 Abandoned US20090311258A1 (en) 2006-08-02 2007-05-26 Medicament for lct poisoning
US13/483,701 Expired - Fee Related US9066961B2 (en) 2006-08-02 2012-05-30 Medicament for LCT poisoning
US14/724,846 Abandoned US20150344531A1 (en) 2006-08-02 2015-05-29 Medicament for lct poisoning

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/483,701 Expired - Fee Related US9066961B2 (en) 2006-08-02 2012-05-30 Medicament for LCT poisoning
US14/724,846 Abandoned US20150344531A1 (en) 2006-08-02 2015-05-29 Medicament for lct poisoning

Country Status (9)

Country Link
US (3) US20090311258A1 (en)
EP (1) EP2054044B1 (en)
JP (2) JP5345532B2 (en)
AU (1) AU2007280861B2 (en)
CA (1) CA2659684A1 (en)
ES (1) ES2507553T3 (en)
RU (1) RU2465893C2 (en)
UA (1) UA96768C2 (en)
WO (1) WO2008014733A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280286A1 (en) * 2006-08-02 2013-10-24 Johannes Gutenberg-Universitaet Mainz Medicament for lct poisoning
US9315555B2 (en) 2012-04-04 2016-04-19 The Secretary Of State For Health Clostridium difficile antigens

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009324180A1 (en) * 2008-12-03 2010-06-10 Boehringer Ingelheim Vetmedica Gmbh Process for production of vaccines
PL2773648T3 (en) * 2011-09-29 2020-03-31 ETH Zürich Pharmaceutical compounds for use in the therapy of clostridium difficile infection
CA2858519A1 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
CA2863536A1 (en) * 2012-03-02 2013-09-06 Regeneron Pharmaceuticals, Inc. Human antibodies to clostridium difficile toxins
CN111499738B (en) * 2020-06-03 2022-04-05 郑州师范学院 Antibody for resisting clostridium difficile enterotoxin A

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929438A (en) * 1988-05-13 1990-05-29 Kabushiki Kaisha Sanwa Kagaku Kenkyusho Preventives and remedies for medicinal and alcoholic poisoning

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705811D0 (en) * 1987-03-11 1987-04-15 Research Corp Ltd Inositol derivatives
JPH0429621Y2 (en) * 1988-01-23 1992-07-17
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
FR2770844A1 (en) * 1997-11-10 1999-05-14 Inst Nat Sante Rech Med INHIBITORS OF CLOSTRIDAL TOXINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US6013635A (en) * 1998-05-28 2000-01-11 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions
US6415234B1 (en) * 1998-08-03 2002-07-02 Glyco Design Inc. Designing inhibitors for glycosyltransferases
CA2366794A1 (en) * 1999-04-09 2000-10-19 The Johns Hopkins University Channel forming toxins as antiviral agents
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP1240181A2 (en) * 1999-12-15 2002-09-18 Cubist Pharmaceuticals, Inc. Daptomycin analogs as antibacterial agents
EP1503768B1 (en) * 2002-04-29 2015-10-28 NormOxys, Inc. Inositol pyrophosphates, and use thereof
DE60324924D1 (en) * 2002-06-26 2009-01-08 Nestec Sa
HUE025624T2 (en) * 2002-07-26 2016-04-28 The Walter And Eliza Hall Inst Of Medical Res Immunogenic compositions and diagnostic and therapeutic uses thereof
JP4557514B2 (en) * 2003-07-15 2010-10-06 住友電工焼結合金株式会社 Internal gear pump and inner rotor of the pump
US7625559B2 (en) * 2004-02-06 2009-12-01 University Of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
CA2578250C (en) * 2004-07-26 2013-03-05 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
CA2583666A1 (en) * 2004-10-13 2006-04-27 Ilypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
US20090170790A1 (en) * 2004-10-25 2009-07-02 Biswajit Das Ketolide derivatives as antibacterial agents
WO2007060618A2 (en) * 2005-11-23 2007-05-31 Ranbaxy Laboratories Limited Macrolides derivatives as antibacterial agents
US20080003329A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
ES2507553T3 (en) * 2006-08-02 2014-10-15 Johannes Gutenberg-Universität Mainz LCT poisoning drug
US20110218176A1 (en) * 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US8110551B2 (en) * 2008-01-22 2012-02-07 The Trustees Of The University Of Pennsylvania Cytolethal distending toxin and use thereof
US20100137563A1 (en) * 2008-12-03 2010-06-03 Northwestern University Cysteine Protease Autoprocessing of Fusion Proteins
AU2009324180A1 (en) * 2008-12-03 2010-06-10 Boehringer Ingelheim Vetmedica Gmbh Process for production of vaccines
US20130012687A1 (en) * 2009-09-21 2013-01-10 The Board Of Trustees Of The Leland Stanford Junior University Inducible self-cleaving protease tag and method of purifying recombinant proteins using the same
KR101854820B1 (en) * 2009-09-25 2018-05-04 샤이어 오펀 테라피즈 게엠베하 Novel NPR-B Agonists
WO2012138963A1 (en) * 2011-04-06 2012-10-11 The Board Of Regents Of The University Of Texas System Inositol hexakisphosphate analogs and uses thereof
TWI686402B (en) * 2011-04-22 2020-03-01 美商惠氏有限責任公司 Compositions relating to a mutant clostridium difficile toxin and methods thereof
US9770500B2 (en) * 2011-05-31 2017-09-26 The Board Of Regents Of The University Of Texas System S-nitrosylation of glucosylating toxins and uses therefor
PL2773648T3 (en) * 2011-09-29 2020-03-31 ETH Zürich Pharmaceutical compounds for use in the therapy of clostridium difficile infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929438A (en) * 1988-05-13 1990-05-29 Kabushiki Kaisha Sanwa Kagaku Kenkyusho Preventives and remedies for medicinal and alcoholic poisoning

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280286A1 (en) * 2006-08-02 2013-10-24 Johannes Gutenberg-Universitaet Mainz Medicament for lct poisoning
US9066961B2 (en) * 2006-08-02 2015-06-30 Johannes Gutenberg-Universitaet Mainz Medicament for LCT poisoning
US9315555B2 (en) 2012-04-04 2016-04-19 The Secretary Of State For Health Clostridium difficile antigens
US9896514B2 (en) 2012-04-04 2018-02-20 The Secretary Of State For Health Clostridium difficile antigens

Also Published As

Publication number Publication date
AU2007280861B2 (en) 2013-02-07
US9066961B2 (en) 2015-06-30
EP2054044A1 (en) 2009-05-06
RU2465893C2 (en) 2012-11-10
JP2009545536A (en) 2009-12-24
EP2054044B1 (en) 2014-07-23
WO2008014733A1 (en) 2008-02-07
CA2659684A1 (en) 2008-02-07
US20150344531A1 (en) 2015-12-03
WO2008014733A9 (en) 2009-01-29
JP5345532B2 (en) 2013-11-20
JP5777594B2 (en) 2015-09-09
JP2013067630A (en) 2013-04-18
RU2009107138A (en) 2010-09-10
UA96768C2 (en) 2011-12-12
ES2507553T3 (en) 2014-10-15
AU2007280861A1 (en) 2008-02-07
US20130280286A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
US20150344531A1 (en) Medicament for lct poisoning
Zhang et al. Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium
US11441141B2 (en) Methods for the manufacture of proteolytically processed polypeptides
EP2776457B1 (en) Neurotoxins exhibiting shortened biological activity
EP3162894B1 (en) Methods for the manufacture of proteolytically processed polypeptides
CN112105379A (en) Neurotoxin-like toxins and uses thereof
Turk Discovery and development of anthrax lethal factor metalloproteinase inhibitors
US20160326222A1 (en) Clostridium difficile vaccine
KR20170017802A (en) METHOD FOR TREATING INFECTIOUS DISEASES USING A COMPOSITION COMPRISING PLASMA-DERIVED IMMUNOGLOBULIN M (IgM)
RU2727402C1 (en) Methods for producing proteolytically processed polypeptides
CN101516359B (en) Medicament for LCT poisoning
DE102007004938A1 (en) Medicament for avoiding or alleviating large clostridial cytotoxins, comprises an effector, which is an inhibitor or activator of the protease activity of large clostridial cytotoxins
Craven Functional analysis of Clostridium sordellii lethal and hemorrhagic toxins
WO2021144794A1 (en) Compounds for use in treatment and/or prevention of clostridial neurotoxins intoxication
Rani et al. In-VivoNeutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain
Goldman et al. Serum-mediated cleavage of Bacillus anthracis Protective Antigen is a two-step

Legal Events

Date Code Title Description
AS Assignment

Owner name: JOHANNES GUTENBERG-UNIVERSITAET MAINZ, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VON EICHELSTREIBER, CHRISTOPH;REINEKE, JESSICA;TENZER, STEFAN;AND OTHERS;SIGNING DATES FROM 20090415 TO 20090502;REEL/FRAME:022896/0818

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION